AI Engines For more Details: Perplexity Kagi Labs You
Prostate Cancer: Flutamide is used in combination with other medications or treatments (such as surgery or radiation therapy) for the management of prostate cancer. It belongs to a class of medications called antiandrogens, which work by blocking the effects of androgens (male hormones) on the prostate gland. By inhibiting the action of androgens, flutamide helps slow down the growth and spread of prostate cancer cells, thereby delaying disease progression and improving survival outcomes in some patients with advanced prostate cancer.
Androgen Deprivation Therapy (ADT): Flutamide is often used as part of androgen deprivation therapy (ADT) in patients with metastatic prostate cancer or those at high risk of disease recurrence after initial treatment. ADT aims to reduce the levels of circulating androgens in the body or block their action on cancer cells to inhibit tumor growth and improve treatment response.
Hormone-Refractory Prostate Cancer: In some cases, flutamide may be prescribed for the treatment of hormone-refractory (androgen-independent) prostate cancer, which no longer responds to hormonal therapies such as surgical castration or medical ADT with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. Flutamide may be used alone or in combination with other medications to manage symptoms and slow down disease progression in patients with hormone-refractory prostate cancer.
Side Effects: Common side effects of flutamide may include hot flashes, decreased libido (sex drive), erectile dysfunction (impotence), breast tenderness or enlargement (gynecomastia), diarrhea, nausea, vomiting, fatigue, and liver toxicity (elevated liver enzymes). Flutamide may also cause rare but serious adverse effects such as liver damage, hepatitis, and liver failure, which may manifest as jaundice (yellowing of the skin or eyes), abdominal pain, dark urine, or unusual fatigue. Patients taking flutamide should be closely monitored for signs of liver toxicity, and treatment should be discontinued if severe liver injury occurs.
Drug Interactions: Flutamide may interact with certain medications, including warfarin (an anticoagulant), leading to an increased risk of bleeding, and insulin or oral antidiabetic drugs, resulting in changes in blood sugar levels. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking before starting flutamide therapy to avoid potential drug interactions.
Long-Term Use: Flutamide is typically used for a limited duration as part of a comprehensive treatment regimen for prostate cancer. Long-term use of flutamide may increase the risk of adverse effects, including liver toxicity and gastrointestinal disturbances. The duration of flutamide therapy should be determined by the treating physician based on the individual patient's response to treatment and overall health status.
Follow-up Care: Patients receiving flutamide therapy for prostate cancer should undergo regular monitoring of prostate-specific antigen (PSA) levels and periodic evaluations of liver function tests to assess treatment response and detect potential complications. Close collaboration between the patient, oncologist, and other members of the healthcare team is essential to ensure optimal management and supportive care throughout the treatment course.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 1.1 | 0.6 | 0.83 |
| ADHD | 2.8 | 0.3 | 8.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 2.5 | 0.5 | 4 |
| Allergies | 4.1 | 3.1 | 0.32 |
| Allergy to milk products | 1.6 | 0.9 | 0.78 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 4.6 | 6.3 | -0.37 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.6 | 1.17 |
| Ankylosing spondylitis | 3.1 | 1.8 | 0.72 |
| Anorexia Nervosa | 0.8 | 2.5 | -2.13 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 3.1 | 1.6 | 0.94 |
| Atherosclerosis | 1.5 | 1.9 | -0.27 |
| Atrial fibrillation | 2.3 | 2.3 | 0 |
| Autism | 6.1 | 5.3 | 0.15 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 1.7 | 1.1 | 0.55 |
| Brain Trauma | 1.1 | 1.1 | 0 |
| Breast Cancer | 1 | 0.3 | 2.33 |
| Cancer (General) | 0.6 | 1.2 | -1 |
| Carcinoma | 3.1 | 1.2 | 1.58 |
| Celiac Disease | 1.8 | 1.5 | 0.2 |
| Cerebral Palsy | 0.8 | 1.1 | -0.38 |
| Chronic Fatigue Syndrome | 3.3 | 3.5 | -0.06 |
| Chronic Kidney Disease | 2.4 | 2.8 | -0.17 |
| Chronic Lyme | 0 | 0.8 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.7 | 0 |
| Chronic Urticaria (Hives) | 1.3 | 0.6 | 1.17 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1.1 | 0.45 |
| Cognitive Function | 1.7 | 1.3 | 0.31 |
| Colorectal Cancer | 5 | 2.5 | 1 |
| Constipation | 1.6 | 0.7 | 1.29 |
| Coronary artery disease | 2.7 | 2 | 0.35 |
| COVID-19 | 3.8 | 6.8 | -0.79 |
| Crohn's Disease | 5.2 | 3.2 | 0.63 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | 0.4 | 0.25 |
| cystic fibrosis | 1.3 | 0.8 | 0.63 |
| d-lactic acidosis (one form of brain fog) | 0.8 | 0.8 | |
| deep vein thrombosis | 3 | 1.4 | 1.14 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 4.9 | 6.4 | -0.31 |
| Dermatomyositis | 0.8 | 0.8 | |
| Eczema | 2.5 | 0.6 | 3.17 |
| Endometriosis | 2.2 | 2 | 0.1 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.7 | 0.3 | 8 |
| erectile dysfunction | 2 | 2 | |
| Fibromyalgia | 1.2 | 1.7 | -0.42 |
| Functional constipation / chronic idiopathic constipation | 4.3 | 2.9 | 0.48 |
| gallstone disease (gsd) | 2.1 | 0.8 | 1.63 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.6 | 0.5 |
| Generalized anxiety disorder | 2.7 | 1.6 | 0.69 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.4 | 0.8 | 0.75 |
| Graves' disease | 0.9 | 2 | -1.22 |
| Gulf War Syndrome | 0.8 | 0.3 | 1.67 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 2.1 | 1.5 | 0.4 |
| Heart Failure | 4 | 1.4 | 1.86 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.9 | 1.9 | |
| High Histamine/low DAO | 1.6 | 0.3 | 4.33 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 1 | 0.3 | 2.33 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 2.6 | 3.2 | -0.23 |
| Hypothyroidism | 0.5 | 0.3 | 0.67 |
| Hypoxia | 2 | 0.6 | 2.33 |
| IgA nephropathy (IgAN) | 1.7 | 2.7 | -0.59 |
| Inflammatory Bowel Disease | 5.4 | 6.4 | -0.19 |
| Insomnia | 1.8 | 2 | -0.11 |
| Intelligence | 1 | 0.6 | 0.67 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 5.1 | 2.9 | 0.76 |
| ischemic stroke | 1.1 | 1.7 | -0.55 |
| Liver Cirrhosis | 5.2 | 2.7 | 0.93 |
| Long COVID | 4.2 | 4.2 | 0 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 0.3 | 2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.9 | 0.6 | 2.17 |
| ME/CFS with IBS | 0.5 | 0.9 | -0.8 |
| ME/CFS without IBS | 1.2 | 0.3 | 3 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.5 | 0.2 |
| Metabolic Syndrome | 5.4 | 3.5 | 0.54 |
| Mood Disorders | 5.2 | 5.2 | 0 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 3.4 | 3.8 | -0.12 |
| Multiple system atrophy (MSA) | 0.6 | 0.3 | 1 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.2 | -2.2 | |
| Neuropathy (all types) | 0.3 | 1.8 | -5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.6 | 2.5 | 0.84 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 7.3 | 4.9 | 0.49 |
| obsessive-compulsive disorder | 2.8 | 3.3 | -0.18 |
| Osteoarthritis | 2.5 | 0.9 | 1.78 |
| Osteoporosis | 2.4 | 0.6 | 3 |
| pancreatic cancer | 1.1 | 0.3 | 2.67 |
| Parkinson's Disease | 4.8 | 5.1 | -0.06 |
| Polycystic ovary syndrome | 4.2 | 2.8 | 0.5 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | 1.1 | -2.67 |
| Primary sclerosing cholangitis | 1.1 | 1.5 | -0.36 |
| Psoriasis | 1.7 | 2.3 | -0.35 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.2 | 2.8 | 1.21 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 3.4 | 1.9 | 0.79 |
| scoliosis | 1 | 0.7 | 0.43 |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 1.8 | 0.6 | 2 |
| Sleep Apnea | 1.2 | 1.4 | -0.17 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 1.6 | |
| Stress / posttraumatic stress disorder | 1.6 | 1.4 | 0.14 |
| Systemic Lupus Erythematosus | 3.7 | 1.4 | 1.64 |
| Tic Disorder | 1 | 0.9 | 0.11 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 3.2 | 2 | 0.6 |
| Type 2 Diabetes | 5.8 | 3 | 0.93 |
| Ulcerative colitis | 3.2 | 4.1 | -0.28 |
| Unhealthy Ageing | 3.4 | 1.7 | 1 |
| Vitiligo | 1.2 | 0.8 | 0.5 |
